Unak P.Teksoz S.Biber Muftuler F.Z.Medine E.I.Acar C.Yurekli Y.2019-10-272019-10-2720080236-57310236-5731https://doi.org/10.1007/s10967-007-6934-4https://hdl.handle.net/11454/27436The aim of the current study was to design a nucleotide-based radiopharmaceutical which could be labeled with 99mTc and to investigate its radiopharmaceutical efficiency and stability. GHA (glucoheptonate) was used as bifunctional chelate. GHA was labeled with 99mTc by SnCl2 reduction method first, and then G (guanine) was conjugated with 99mTc-GHA at 90°C. In order to determine its radiopharmaceutical stability, thin layer radio chromatography (TLRC) and electrophoresis were employed. In addition, the results were confirmed using high performance liquid radio chromatography (HPLRC). Scintigraphic imaging was performed on rats with mammary tumors, while tissue distribution was determined on Albino Wistar rats. Labeling yield was found to be over 95% and the labeled complex maintained its stability during the study period. The lipophilicity of the 99mTc-GHG was measured and the partition coefficient (logP) of the labeled compound calculated. The results demonstrated that the uptake of 99mTc-GHG (99mTc- glucoheptonate-guanine) reached its maximum at 3 hours p.i. in stomach and intestines. Main way of excretion was renal. Hepatobiliary excretion was also observed. In conclusion, 99mTc-GHG may be useful as a nucleotide-based radiopharmaceutical for in vivo applications. © 2008 Springer Science+Business Media, LLC.en10.1007/s10967-007-6934-4info:eu-repo/semantics/closedAccessArticle2752379385Q2